AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer

Acta Oncol. 2019 Nov;58(11):1660-1664. doi: 10.1080/0284186X.2019.1637540. Epub 2019 Jul 9.

Authors

Andreas Josefsson^{1

2

3}, Jan-Erik Damber¹, Karin Welén¹

Affiliations

¹ Department of Urology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
² Department of Surgical and Perioperative Sciences, Urology & Andrology, Umeå University, Umeå, Sweden.
³ Wallenberg Center for Molecular Medicine, Umeå University, Umeå, Sweden.

PMID: 31286815
DOI: 10.1080/0284186X.2019.1637540

No abstract available

Publication types

Letter

MeSH terms

Androgen Antagonists / therapeutic use
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics*
Humans
Male
Neoplasm Metastasis
Neoplastic Cells, Circulating / metabolism*
Prognosis
Prostatic Neoplasms / blood
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / genetics*
Prostatic Neoplasms, Castration-Resistant / blood
Prostatic Neoplasms, Castration-Resistant / diagnosis
Prostatic Neoplasms, Castration-Resistant / drug therapy
Prostatic Neoplasms, Castration-Resistant / genetics
Protein Isoforms / blood
Protein Isoforms / genetics
RNA, Messenger / blood
Receptors, Androgen / blood
Receptors, Androgen / genetics*
Survival Analysis

Substances

Androgen Antagonists
Antineoplastic Agents
Biomarkers, Tumor
Protein Isoforms
RNA, Messenger
Receptors, Androgen